1. Effects of ketamine in methicillin-resistant Staphylococcus aureus and in silico interaction with sortase A
- Author
-
Thiago M Cândido, Lisandra Juvêncio da Silva, Cecília Rocha da Silva, Jacilene Silva, Manoel Odorico de Moraes, Hélio Vitoriano Nobre Júnior, Thais Lima Ferreira, Bruno C. Cavalcanti, João Batista de Andrade Neto, Lívia Gurgel do Amaral Valente Sá, Vitória Pessoa de Farias Cabral, Fátima Daiana Dias Barroso, Anderson Ramos da Silva, Emmanuel Silva Marinho, Wildson Max Barbosa da Silva, and Tatiana do Nascimento Paiva Coutinho
- Subjects
In silico ,Immunology ,Human pathogen ,General Medicine ,Biology ,Skin infection ,medicine.disease_cause ,medicine.disease ,Applied Microbiology and Biotechnology ,Microbiology ,Methicillin-resistant Staphylococcus aureus ,Staphylococcus aureus ,Sortase A ,Genetics ,medicine ,Molecular Biology - Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the main human pathogens and is responsible for many diseases, ranging from skin infections to more invasive infections. These infections are dangerous and expensive to treat because these strains are resistant to a large number of conventional antibiotics. Thus, the antibacterial effect of ketamine against MRSA strains, its mechanism of action, and in silico interaction with sortase A were evaluated. The antibacterial effect of ketamine was assessed using the broth microdilution method. Subsequently, the mechanism of action was assessed using flow cytometry and molecular docking assays with sortase A. Our results showed that ketamine has a significant antibacterial activity against MRSA strains in the range of 2.49–3.73 mM. Their mechanism of action involves alterations in membrane integrity and DNA damage, reducing cell viability, and inducing apoptosis. In addition, ketamine had an affinity for S. aureus sortase A. These results indicate that this compound can be used as an alternative to develop new strategies to combat infections caused by MRSA.
- Published
- 2021
- Full Text
- View/download PDF